Targeted Therapy to Increase RAI Uptake in Metastatic DTC
This study tests whether targeted drugs that block genetic drivers of papillary thyroid cancer can help the body take up radioactive iodine treatment better. Researchers believe these drugs may make existing thyroid cancer treatments more effective, especially for patients whose cancer has spread to other parts of the body.
Key Objective:The trial is testing whether targeted therapy can improve how well radioactive iodine treatment works in treating metastatic differentiated thyroid cancer.
Who to Consider:Children and adolescents with papillary thyroid cancer that has spread to other parts of the body and does not respond well to standard radioactive iodine therapy should consider enrolling.
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
Papillary thyroid cancer (PTC) is a common type of differentiated thyroid cancer (DTC) in children and represents the second most common cancer in adolescent females. Recently targeted drugs that block many of the genetic drivers of DTC have become available. While Investigators know that these drugs shrink DTC tumors in many cases, the impact on radioactive iodine (RAI) avidity has not been systematically studied.
Eligibility Criteria
Inclusion Criteria (Prospective Cohort): 1. Patients with a histologic diagnosis of differentiated thyroid cancer 2. Presence of an neurotrophic tyrosine kinase receptors (NTRK)-fusion, RET-fusion, anaplastic lymphoma kinase (ALK)-fusion, BRAF V600 mutation, BRAF-fusion or other targetable alteration identified in a Clinical Laboratory Improvement Amendments/College of American Pathologists (CLIA/CAP) laboratory 3. Anatomically evaluable disease on chest Computed tomography (CT) meeting oneo f the following criteria (obtained within 180 days of enrollment): 1. multiple (10 or more) noncalcified solid pulmonary nodules visible on CT and/or 2. enlarging, discrete pulmonary nodules visible on CT of any number consistent with metastatic disease 4. Patients for whom systemic therapy with an oncogene-specific kinase inhibitor is planned from commercial supply or as part of a separate therapeutic clinical trial (that does not include data sharing with this protocol)/compassionate access proto